The CELLEX is comparable to the UVAR‐XTS for the treatment of acute and chronic graft versus host disease (GVHD)

MLA

Maryna Tarbunova, et al. “The CELLEX Is Comparable to the UVAR‐XTS for the Treatment of Acute and Chronic Graft versus Host Disease (GVHD).” Transfusion, vol. 60, Jan. 2020, pp. 351–57. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4902ed18cdbfb695cb34f1b1ffc3da69&authtype=sso&custid=ns315887.

APA

Maryna Tarbunova, George J. Despotis, Brenda J. Grossman, & Amber Afzal. (2020). The CELLEX is comparable to the UVAR‐XTS for the treatment of acute and chronic graft versus host disease (GVHD). Transfusion, 60, 351–357.

Chicago

Maryna Tarbunova, George J. Despotis, Brenda J. Grossman, and Amber Afzal. 2020. “The CELLEX Is Comparable to the UVAR‐XTS for the Treatment of Acute and Chronic Graft versus Host Disease (GVHD).” Transfusion 60 (January): 351–57. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4902ed18cdbfb695cb34f1b1ffc3da69&authtype=sso&custid=ns315887.